Research Focus

Although Warfarin was first approved for medical use over 60 years ago it remains the most widely prescribed oral anticoagulation agent for long-term prophylaxis and treatment of thromboembolic disorders. Since warfarin has a narrow therapeutic index, and individual response to the drug can be quite variable, the discovery of the close association of its dose requirements with genetics polymorphisms in recent years has re-ignited interest to optimize treatment. Our study aims to compare the clinical benefits of genetics-guided dosing, based on determination of CYP2C9 and VKORC1 SNPs versus traditional dosing schedules.

Principal Investigator

Co-PI: Goh Boon Cher (NUHS)

Co-Investigators: Lee Soo Chin(NUHS), James Yip (NUHS), Wu Tuck Seng (NUHS), Liam Brunham (TLGM), Bee Ping Chong (University of Malaya), Chee Kok Han (University of Malaya)

Principal Investigator

Co-PI: Goh Boon Cher (NUHS)

Co-Investigators: Lee Soo Chin(NUHS), James Yip (NUHS), Wu Tuck Seng (NUHS), Liam Brunham (TLGM)

Co-Investigators (University of Malaya): Bee Ping Chong, Chee Kok Han